Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

Reprogramming Fibroblasts into Oligodendrocyte Progenitor Cells May Lead to Cure for Multiple Sclerosis and Cerebral Palsy

By BiotechDaily International staff writers
Posted on 02 May 2013
Working with mouse tissues, investigators have developed a method for converting skin or lung fibroblasts into fully functional oligodendrocytes, the type of cell responsible for myelinating the neurons of the brain and which are lost in myelin disorders such as multiple sclerosis and cerebral palsy.

Cell-based therapies for myelin disorders require technologies to generate functional oligodendrocyte progenitor cells (OPCs). In this regard, investigators at Case Western Reserve School of Medicine (Cleveland, OH, USA) described the direct conversion of mouse embryonic and lung fibroblasts to induced oligodendrocyte progenitor cells (iOPCs) using sets of either three or eight defined transcription factors.

They reported in the April 14, 2013, online edition of the journal Nature Biotechnology that the iOPCs exhibited a bipolar morphology and global gene expression profile consistent with bona fide OPCs. They could be expanded in vitro for at least five passages while retaining the ability to differentiate into multiprocessed oligodendrocytes. When transplanted to hypomyelinated mice, iOPCs were capable of ensheathing host axons and generating compact myelin.

“The myelin repair field has been hampered by an inability to rapidly generate safe and effective sources of functional oligodendrocytes,” said contributing author Dr. Robert Miller, professor of neurosciences at the Case Western Reserve School of Medicine. “The new technique may overcome all of these issues by providing a rapid and streamlined way to directly generate functional myelin producing cells.”

“It is cellular alchemy,” explained senior author Dr. Paul Tesar, assistant professor of genetics and genome sciences at Case Western Reserve School of Medicine. “We are taking a readily accessible and abundant cell and completely switching its identity to become a highly valuable cell for therapy.”

Related Links:

Case Western Reserve School of Medicine




Channels

Drug Discovery

view channel
Image: Scanning electron microscope (SEM) image of a field of polypyrrole nanowires (Photo courtesy of Dr. Richard Borgens, Purdue University).

Novel Controlled-Release Drug Delivery System Heals Spinal Inflammation in Mouse Model

A novel drug delivery system that allows controllable release of an anti-inflammatory agent directly to the site of inflammation or injury was tested successfully in a mouse model. Investigators at... Read more

Business

view channel

Biopharm Startup to Commercialize Antibody Therapy for Drug Resistant Cancers

A biopharm startup company has licensed the rights to commercialize an antibody-based approach for treatment of drug resistant cancers. The new company, CadheRx Therapeutics (La Jolla, CA, USA), entered into a licensing agreement with Stony Brook University (NY, USA) to develop and market an anticancer technology derived... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.